{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:58:09Z","timestamp":1794434289685,"version":"4.9.1"},"publisher-location":"Totowa, NJ","reference-count":65,"publisher":"Humana Press","isbn-type":[{"value":"9781617799204","type":"print"},{"value":"9781617799211","type":"electronic"}],"license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012]]},"DOI":"10.1007\/978-1-61779-921-1_1","type":"book-chapter","created":{"date-parts":[[2012,11,30]],"date-time":"2012-11-30T14:48:14Z","timestamp":1354286894000},"page":"1-26","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":341,"title":["Therapeutic Proteins"],"prefix":"10.1007","author":[{"given":"Dimiter S.","family":"Dimitrov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,5,24]]},"reference":[{"key":"1_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nri1837","volume":"6","author":"PJ Carter","year":"2006","unstructured":"Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6:343\u2013357","journal-title":"Nat Rev Immunol"},{"key":"1_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nrd1957","volume":"5","author":"D Schrama","year":"2006","unstructured":"Schrama D, Reisfeld RA, Becker JC (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5:147\u2013159","journal-title":"Nat Rev Drug Discov"},{"key":"1_CR3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nm0303-269","volume":"9","author":"TA Waldmann","year":"2003","unstructured":"Waldmann TA (2003) Immunotherapy: past, present and future. Nat Med 9:269\u2013277","journal-title":"Nat Med"},{"key":"1_CR4","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/nrmicro974","volume":"2","author":"A Casadevall","year":"2004","unstructured":"Casadevall A, Dadachova E, Pirofski LA (2004) Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2:695\u2013703","journal-title":"Nat Rev Microbiol"},{"key":"1_CR5","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.yexcr.2011.02.013","volume":"317","author":"PJ Carter","year":"2011","unstructured":"Carter PJ (2011) Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res 317:1261\u20131269","journal-title":"Exp Cell Res"},{"key":"1_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.4161\/mabs.2.3.11779","volume":"2","author":"DS Dimitrov","year":"2010","unstructured":"Dimitrov DS (2010) Therapeutic antibodies, vaccines and antibodyomes. MAbs 2:347\u2013356","journal-title":"MAbs"},{"key":"1_CR7","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nbt0910-917","volume":"28","author":"G Walsh","year":"2010","unstructured":"Walsh G (2010) Biopharmaceutical benchmarks 2010. Nat Biotechnol 28:917\u2013924","journal-title":"Nat Biotechnol"},{"key":"1_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrd2399","volume":"7","author":"B Leader","year":"2008","unstructured":"Leader B, Baca QJ, Golan DE (2008) Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 7:21\u201339","journal-title":"Nat Rev Drug Discov"},{"key":"1_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-59745-554-1_1","volume":"525","author":"DS Dimitrov","year":"2009","unstructured":"Dimitrov DS, Marks JD (2009) Therapeutic antibodies: current state and future trends\u2014is a paradigm change coming soon? Methods Mol Biol 525:1\u201327","journal-title":"Methods Mol Biol"},{"key":"1_CR10","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/nrd2637","volume":"7","author":"A Ashkenazi","year":"2008","unstructured":"Ashkenazi A (2008) Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 7:1001\u20131012","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"1_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.4161\/mabs.3.5.17334","volume":"3","author":"A Beck","year":"2011","unstructured":"Beck A, Reichert JM (2011) Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs 3(5):415\u2013416","journal-title":"MAbs"},{"key":"1_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4161\/mabs.3.1.13895","volume":"3","author":"JM Reichert","year":"2011","unstructured":"Reichert JM (2011) Antibody-based therapeutics to watch in 2011. MAbs 3:76\u201399","journal-title":"MAbs"},{"key":"1_CR13","doi-asserted-by":"publisher","first-page":"695","DOI":"10.4161\/mabs.2.6.13603","volume":"2","author":"JM Reichert","year":"2010","unstructured":"Reichert JM (2010) Metrics for antibody therapeutics development. MAbs 2:695\u2013700","journal-title":"MAbs"},{"key":"1_CR14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G Kohler","year":"1975","unstructured":"Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495\u2013497","journal-title":"Nature"},{"key":"1_CR15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1073\/pnas.76.1.106","volume":"76","author":"DV Goeddel","year":"1979","unstructured":"Goeddel DV, Kleid DG, Bolivar F, Heyneker HL, Yansura DG, Crea R, Hirose T, Kraszewski A, Itakura K, Riggs AD (1979) Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc Natl Acad Sci USA 76:106\u2013110","journal-title":"Proc Natl Acad Sci USA"},{"key":"1_CR16","first-page":"178","volume":"11","author":"Y Feng","year":"2008","unstructured":"Feng Y, Dimitrov DS (2008) Monoclonal antibodies against components of the IGF system for cancer treatment. Curr Opin Drug Discov Devel 11:178\u2013185","journal-title":"Curr Opin Drug Discov Devel"},{"key":"1_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jmb.2005.04.049","volume":"350","author":"H Wu","year":"2005","unstructured":"Wu H, Pfarr DS, Tang Y, An LL, Patel NK, Watkins JD, Huse WD, Kiener PA, Young JF (2005) Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol 350:126\u2013144","journal-title":"J Mol Biol"},{"key":"1_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.copbio.2007.04.010","volume":"18","author":"A Skerra","year":"2007","unstructured":"Skerra A (2007) Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotechnol 18:295\u2013304","journal-title":"Curr Opin Biotechnol"},{"key":"1_CR19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/COH.0b013e328322f95e","volume":"4","author":"W Chen","year":"2009","unstructured":"Chen W, Dimitrov DS (2009) Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors. Curr Opin HIV AIDS 4:112\u2013117","journal-title":"Curr Opin HIV AIDS"},{"key":"1_CR20","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jmb.2008.07.054","volume":"382","author":"W Chen","year":"2008","unstructured":"Chen W, Zhu Z, Feng Y, Xiao X, Dimitrov DS (2008) Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain. J Mol Biol 382:779\u2013789","journal-title":"J Mol Biol"},{"key":"1_CR21","doi-asserted-by":"publisher","first-page":"17121","DOI":"10.1073\/pnas.0805297105","volume":"105","author":"W Chen","year":"2008","unstructured":"Chen W, Zhu Z, Feng Y, Dimitrov DS (2008) Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci USA 105:17121\u201317126","journal-title":"Proc Natl Acad Sci USA"},{"key":"1_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.antiviral.2010.08.004","volume":"88","author":"W Chen","year":"2010","unstructured":"Chen W, Xiao X, Wang Y, Zhu Z, Dimitrov DS (2010) Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates. Antiviral Res 88:107\u2013115","journal-title":"Antiviral Res"},{"key":"1_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4161\/mabs.1.1.7480","volume":"1","author":"DS Dimitrov","year":"2009","unstructured":"Dimitrov DS (2009) Engineered CH2 domains (nanoantibodies). MAbs 1:26\u201328","journal-title":"MAbs"},{"key":"1_CR24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.bbrc.2009.07.044","volume":"387","author":"X Xiao","year":"2009","unstructured":"Xiao X, Feng Y, Vu BK, Ishima R, Dimitrov DS (2009) A large library based on a novel (CH2) scaffold: identification of HIV-1 inhibitors. Biochem Biophys Res Commun 387:387\u2013392","journal-title":"Biochem Biophys Res Commun"},{"key":"1_CR25","doi-asserted-by":"publisher","first-page":"14203","DOI":"10.1074\/jbc.M900769200","volume":"284","author":"R Gong","year":"2009","unstructured":"Gong R, Vu BK, Feng Y, Prieto DA, Dyba MA, Walsh JD, Prabakaran P, Veenstra TD, Tarasov SG, Ishima R, Dimitrov DS (2009) Engineered human antibody constant domains with increased stability. J Biol Chem 284:14203\u201314210","journal-title":"J Biol Chem"},{"issue":"3","key":"1_CR26","doi-asserted-by":"publisher","first-page":"27288","DOI":"10.1074\/jbc.M111.254219","volume":"286","author":"R Gong","year":"2011","unstructured":"Gong R, Wang Y, Feng Y, Zhao Q, Dimitrov DS (2011) Shortened engineered human antibody CH2 domains: increased stability and binding to the human neonatal receptor. J Biol Chem 286(3):27288\u201327293","journal-title":"J Biol Chem"},{"key":"1_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrd3365","volume":"10","author":"XR Jiang","year":"2011","unstructured":"Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, Chung S, Strouse R, Mire-Sluis A, Schenerman M (2011) Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 10:101\u2013111","journal-title":"Nat Rev Drug Discov"},{"key":"1_CR28","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1517\/17425250802525496","volume":"4","author":"J Descotes","year":"2008","unstructured":"Descotes J, Gouraud A (2008) Clinical immunotoxicity of therapeutic proteins. Expert Opin Drug Metab Toxicol 4:1537\u20131549","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1_CR29","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMoa063842","volume":"355","author":"G Suntharalingam","year":"2006","unstructured":"Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018\u20131028","journal-title":"N Engl J Med"},{"key":"1_CR30","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2165\/00002018-200831060-00002","volume":"31","author":"SM Ewer","year":"2008","unstructured":"Ewer SM, Ewer MS (2008) Cardiotoxicity profile of trastuzumab. Drug Saf 31:459\u2013467","journal-title":"Drug Saf"},{"key":"1_CR31","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1634\/theoncologist.2008-0012","volume":"13","author":"CH Chung","year":"2008","unstructured":"Chung CH (2008) Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 13:725\u2013732","journal-title":"Oncologist"},{"key":"1_CR32","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1517\/14740330902750114","volume":"8","author":"MC Winter","year":"2009","unstructured":"Winter MC, Hancock BW (2009) Ten years of rituximab in NHL. Expert Opin Drug Saf 8:223\u2013235","journal-title":"Expert Opin Drug Saf"},{"key":"1_CR33","first-page":"172","volume":"5","author":"C Pendley","year":"2003","unstructured":"Pendley C, Schantz A, Wagner C (2003) Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 5:172\u2013179","journal-title":"Curr Opin Mol Ther"},{"key":"1_CR34","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1387-2656(08)00007-0","volume":"14","author":"H Schellekens","year":"2008","unstructured":"Schellekens H (2008) How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev 14:191\u2013202","journal-title":"Biotechnol Annu Rev"},{"key":"1_CR35","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2174\/138945009787354511","volume":"10","author":"M Onda","year":"2009","unstructured":"Onda M (2009) Reducing the immunogenicity of protein therapeutics. Curr Drug Targets 10:131\u2013139","journal-title":"Curr Drug Targets"},{"key":"1_CR36","first-page":"219","volume":"10","author":"MP Baker","year":"2007","unstructured":"Baker MP, Jones TD (2007) Identification and removal of immunogenicity in therapeutic proteins. Curr Opin Drug Discov Devel 10:219\u2013227","journal-title":"Curr Opin Drug Discov Devel"},{"key":"1_CR37","first-page":"169","volume":"12","author":"P Stas","year":"2009","unstructured":"Stas P, Lasters I (2009) Strategies for preclinical immunogenicity assessment of protein therapeutics. IDrugs 12:169\u2013173","journal-title":"IDrugs"},{"key":"1_CR38","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.coph.2008.08.002","volume":"8","author":"AS De Groot","year":"2008","unstructured":"De Groot AS, McMurry J, Moise L (2008) Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr Opin Pharmacol 8:620\u2013626","journal-title":"Curr Opin Pharmacol"},{"issue":"2\u20133","key":"1_CR39","first-page":"82","volume":"38","author":"AN Emi","year":"2010","unstructured":"Emi AN, de Carvalho JF, Artur Almeida SC, Bonfa E (2010) Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 38(2\u20133):82\u201389","journal-title":"Clin Rev Allergy Immunol"},{"key":"1_CR40","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nri1783","volume":"6","author":"L Hangartner","year":"2006","unstructured":"Hangartner L, Zinkernagel RM, Hengartner H (2006) Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 6:231\u2013243","journal-title":"Nat Rev Immunol"},{"key":"1_CR41","first-page":"103","volume":"12","author":"R Dixit","year":"2009","unstructured":"Dixit R, Coats S (2009) Preclinical efficacy and safety models for mAbs: the challenge of developing effective model systems. IDrugs 12:103\u2013108","journal-title":"IDrugs"},{"key":"1_CR42","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.exphem.2008.04.018","volume":"36","author":"J Castillo","year":"2008","unstructured":"Castillo J, Winer E, Quesenberry P (2008) Newer monoclonal antibodies for hematological malignancies. Exp Hematol 36:755\u2013768","journal-title":"Exp Hematol"},{"key":"1_CR43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/ncponc1298","volume":"6","author":"G Mariani","year":"2009","unstructured":"Mariani G, Fasolo A, De BE, Gianni L (2009) Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol 6:93\u2013104","journal-title":"Nat Clin Pract Oncol"},{"issue":"Suppl 4","key":"1_CR44","doi-asserted-by":"publisher","first-page":"S157","DOI":"10.3816\/CBC.2008.s.012","volume":"8","author":"PL Bedard","year":"2008","unstructured":"Bedard PL, Piccart-Gebhart MJ (2008) Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer. Clin Breast Cancer 8(Suppl 4):S157\u2013S165","journal-title":"Clin Breast Cancer"},{"key":"1_CR45","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2008.10.013","volume":"45","author":"PS Hall","year":"2009","unstructured":"Hall PS, Cameron DA (2009) Current perspective\u2014trastuzumab. Eur J Cancer 45:12\u201318","journal-title":"Eur J Cancer"},{"key":"1_CR46","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10549-007-9885-0","volume":"112","author":"D Cameron","year":"2008","unstructured":"Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:533\u2013543","journal-title":"Breast Cancer Res Treat"},{"key":"1_CR47","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/S1474-4422(08)70260-6","volume":"7","author":"AD Norden","year":"2008","unstructured":"Norden AD, Drappatz J, Wen PY (2008) Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 7:1152\u20131160","journal-title":"Lancet Neurol"},{"key":"1_CR48","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3816\/CBC.2008.n.048","volume":"8","author":"JC Sachdev","year":"2008","unstructured":"Sachdev JC, Jahanzeb M (2008) Evolution of bevacizumab-based therapy in the management of breast cancer. Clin Breast Cancer 8:402\u2013410","journal-title":"Clin Breast Cancer"},{"key":"1_CR49","doi-asserted-by":"publisher","first-page":"31S","DOI":"10.1592\/phco.28.11-supp.31S","volume":"28","author":"DK Patel","year":"2008","unstructured":"Patel DK (2008) Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy 28:31S\u201341S","journal-title":"Pharmacotherapy"},{"key":"1_CR50","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1517\/14712590802715764","volume":"9","author":"DV Tassev","year":"2009","unstructured":"Tassev DV, Cheung NK (2009) Monoclonal antibody therapies for solid tumors. Expert Opin Biol Ther 9:341\u2013353","journal-title":"Expert Opin Biol Ther"},{"key":"1_CR51","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1517\/14712590902735795","volume":"13","author":"EA Hopper-Borge","year":"2009","unstructured":"Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I (2009) Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets 13:339\u2013362","journal-title":"Expert Opin Ther Targets"},{"key":"1_CR52","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.coi.2008.06.012","volume":"20","author":"LG Presta","year":"2008","unstructured":"Presta LG (2008) Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 20:460\u2013470","journal-title":"Curr Opin Immunol"},{"key":"1_CR53","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrd2804","volume":"8","author":"R Jefferis","year":"2009","unstructured":"Jefferis R (2009) Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 8:226\u2013234","journal-title":"Nat Rev Drug Discov"},{"key":"1_CR54","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.coi.2008.05.010","volume":"20","author":"AF Labrijn","year":"2008","unstructured":"Labrijn AF, Aalberse RC, Schuurman J (2008) When binding is enough: nonactivating antibody formats. Curr Opin Immunol 20:479\u2013485","journal-title":"Curr Opin Immunol"},{"key":"1_CR55","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1517\/13543784.17.10.1553","volume":"17","author":"P Kiewe","year":"2008","unstructured":"Kiewe P, Thiel E (2008) Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs 17:1553\u20131558","journal-title":"Expert Opin Investig Drugs"},{"key":"1_CR56","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00262-008-0653-8","volume":"58","author":"J Weber","year":"2009","unstructured":"Weber J (2009) Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 58:823\u2013830","journal-title":"Cancer Immunol Immunother"},{"key":"1_CR57","doi-asserted-by":"publisher","first-page":"20410","DOI":"10.1073\/pnas.0810114105","volume":"105","author":"J Yuan","year":"2008","unstructured":"Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, Roman RA, Terzulli SL, Heywood M, Pogoriler E, Ritter G, Old LJ, Allison JP, Wolchok JD (2008) CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci USA 105:20410\u201320415","journal-title":"Proc Natl Acad Sci USA"},{"key":"1_CR58","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2174\/157488709787047530","volume":"4","author":"AC Bellail","year":"2009","unstructured":"Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C (2009) TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 4:34\u201341","journal-title":"Rev Recent Clin Trials"},{"key":"1_CR59","doi-asserted-by":"publisher","first-page":"565","DOI":"10.4161\/mabs.2.5.12570","volume":"2","author":"Y Feng","year":"2010","unstructured":"Feng Y, Xiao X, Zhu Z, Dimitrov DS (2010) Identification and characterization of a novel agonistic anti-DR4 human monoclonal antibody. MAbs 2:565\u2013570","journal-title":"MAbs"},{"key":"1_CR60","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jim.2003.07.003","volume":"283","author":"MY Zhang","year":"2003","unstructured":"Zhang MY, Shu Y, Phogat S, Xiao X, Cham F, Bouma P, Choudhary A, Feng YR, Sanz I, Rybak S, Broder CC, Quinnan GV, Evans T, Dimitrov DS (2003) Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J Immunol Methods 283:17\u201325","journal-title":"J Immunol Methods"},{"key":"1_CR61","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.virol.2007.01.015","volume":"363","author":"V Choudhry","year":"2007","unstructured":"Choudhry V, Zhang MY, Sidorov IA, Louis JM, Harris I, Dimitrov AS, Bouma P, Cham F, Choudhary A, Rybak SM, Fouts T, Montefiori DC, Broder CC, Quinnan GV Jr, Dimitrov DS (2007) Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology 363:79\u201390","journal-title":"Virology"},{"key":"1_CR62","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2174\/138161207779313669","volume":"13","author":"MY Zhang","year":"2007","unstructured":"Zhang MY, Dimitrov DS (2007) Novel approaches for identification of broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies and improvement of their potency. Curr Pharm Des 13:203\u2013212","journal-title":"Curr Pharm Des"},{"key":"1_CR63","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1002\/jps.21180","volume":"97","author":"H Liu","year":"2008","unstructured":"Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J (2008) Heterogeneity of monoclonal antibodies. J Pharm Sci 97:2426\u20132447","journal-title":"J Pharm Sci"},{"key":"1_CR64","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.addr.2005.12.006","volume":"58","author":"JR Birch","year":"2006","unstructured":"Birch JR, Racher AJ (2006) Antibody production. Adv Drug Deliv Rev 58:671\u2013685","journal-title":"Adv Drug Deliv Rev"},{"key":"1_CR65","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/biot.200800117","volume":"3","author":"JX Zhou","year":"2008","unstructured":"Zhou JX, Tressel T, Yang X, Seewoester T (2008) Implementation of advanced technologies in commercial monoclonal antibody production. Biotechnol J 3:1185\u20131200","journal-title":"Biotechnol J"}],"container-title":["Methods in Molecular Biology","Therapeutic Proteins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-61779-921-1_1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T03:46:13Z","timestamp":1675914373000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-61779-921-1_1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"ISBN":["9781617799204","9781617799211"],"references-count":65,"URL":"https:\/\/doi.org\/10.1007\/978-1-61779-921-1_1","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-1-61779-921-1","asserted-by":"object"}]},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]},"assertion":[{"value":"24 May 2012","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}